The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation

Inclusion Criteria: * Signed informed consent obtained before any trial-related activities. * Men aged \>18 and \<41 years * Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant Exclusion Criteria: * Known or suspected allergy to trial product or related products (Prasugrel, Clopidogrel, Ticlopidine) * Known or suspected hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption * Treatment with an investigational drug within three weeks prior to this trial * Treatment with a drug (e.g. ketoconazole, omeprazole) that interferes with cytochrome P450, the enzyme responsible for the conversion of prasugrel to its active form, three weeks prior to this trial * Participation in an LPS trial within the last 6 weeks * Smoking of more than 5 cigarettes per day * Hereditary deficiency of protein C or S, or a mutation of FV (Leiden), or any other known abnormality affecting coagulation, fibrinolysis or platelet function * History of gastro-duodenal ulcera, cardiovascular disease, vasculitis, diabetes mellitus, or hypertension * History of brain tumor or history of neurosurgery * Hemorrhagic diathesis, trauma or surgery within last 3 months * History of hemorrhagic retinopathy * Hematuria or detection of occult blood in stool sample * Liver or kidney dysfunction * Regular use of medication or abuse of alcohol * Use of any medication within one week prior to the first trial day * Symptoms of a clinically relevant illness in the 3 weeks before the first trial day * Excessive sporting activities * Weight \>95kg and \<60kg